Moyamoya disease pathophysiology: Difference between revisions

Jump to navigation Jump to search
No edit summary
Line 4: Line 4:
==Pathophysiology==
==Pathophysiology==
The constrictions of the arteries in moyamoya disease are unlike the constrictions in [[atherosclerosis]]. In atherosclerosis, the inner layer ([[Lumen (anatomy)|lumen]]) of the arteries suffers an immune reaction, fills with inflammatory cells, and accumulates fatty cells and debris. In moyamoya, the inner layer of the carotid artery overgrows inward to constrict the artery, and the artery also fills with blood clots, which cause strokes.<ref name="Scott">[http://content.nejm.org/cgi/content/full/360/12/1226 Moyamoya Disease and Moyamoya Syndrome], R. Michael Scott and Edward R. Smith, New England Journal of Medicine, 360:1226-1237, March 19, 2009</ref>
The constrictions of the arteries in moyamoya disease are unlike the constrictions in [[atherosclerosis]]. In atherosclerosis, the inner layer ([[Lumen (anatomy)|lumen]]) of the arteries suffers an immune reaction, fills with inflammatory cells, and accumulates fatty cells and debris. In moyamoya, the inner layer of the carotid artery overgrows inward to constrict the artery, and the artery also fills with blood clots, which cause strokes.<ref name="Scott">[http://content.nejm.org/cgi/content/full/360/12/1226 Moyamoya Disease and Moyamoya Syndrome], R. Michael Scott and Edward R. Smith, New England Journal of Medicine, 360:1226-1237, March 19, 2009</ref>
The condition is believed to be hereditary and linked to q25.3, on chromosome 17 [http://emedicine.medscape.com/article/1180952-overview#ClinicalCauses]. They have a higher risk of recurrent stroke and may be experiencing a distinct underlying pathophysiology compared to patients from Japan.  Data suggest a potential benefit with surgery if early diagnosis is made.<ref name="pmid16645133">{{cite journal |author=Hallemeier C, Rich K, Brubb R, Chicoine M, Moran C, Cross D, Zipfel G, Dacey R, Derdeyn |title=Epidemiological features of moyamoya disease in Japan: findings from a nationwide survey |journal=[[Stroke]] |volume=37 |issue= 6|pages=1490–1496 |year=2006 |pmid=16645133 |doi=10.1161/01.STR.0000221787.70503.ca}}</ref>  The pathogenesis of moyamoya disease is unknown.
Once it begins, the process of blockage (vascular occlusion) tends to continue despite any known medical management.  In some people this leads to repeated strokes and severe functional impairment or even death.  In others, this blockage may not cause any symptoms.
Moyamoya can be either congenital or acquired.  Patients with [[Down syndrome]], [[neurofibromatosis]], or [[sickle cell disease]] can develop moyamoya malformations.  It is more common in women than in men, although about a third of those affected are male .<ref name="pmid18048855">{{cite journal |author=Kuriyama S, Kusaka Y, Fujimura M, ''et al.'' |title=Prevalence and clinicoepidemiological features of moyamoya disease in Japan: findings from a nationwide epidemiological survey |journal=Stroke |volume=39 |issue=1 |pages=42–7 |year=2008 |pmid=18048855 |doi=10.1161/STROKEAHA.107.490714 |url=http://stroke.ahajournals.org/cgi/pmidlookup?view=long&pmid=18048855}}</ref>  Brain radiation therapy in children with neurofibromatosis increases the risk of its development.
==References==
==References==
{{reflist|2}}
{{reflist|2}}

Revision as of 21:40, 25 February 2013

Moyamoya disease Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Moyamoya Disease from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

CT

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Moyamoya disease pathophysiology On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Moyamoya disease pathophysiology

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Moyamoya disease pathophysiology

CDC on Moyamoya disease pathophysiology

Moyamoya disease pathophysiology in the news

Blogs on Moyamoya disease pathophysiology

Directions to Hospitals Treating Moyamoya disease

Risk calculators and risk factors for Moyamoya disease pathophysiology

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Vishnu Vardhan Serla M.B.B.S. [2]

Pathophysiology

The constrictions of the arteries in moyamoya disease are unlike the constrictions in atherosclerosis. In atherosclerosis, the inner layer (lumen) of the arteries suffers an immune reaction, fills with inflammatory cells, and accumulates fatty cells and debris. In moyamoya, the inner layer of the carotid artery overgrows inward to constrict the artery, and the artery also fills with blood clots, which cause strokes.[1]

The condition is believed to be hereditary and linked to q25.3, on chromosome 17 [3]. They have a higher risk of recurrent stroke and may be experiencing a distinct underlying pathophysiology compared to patients from Japan. Data suggest a potential benefit with surgery if early diagnosis is made.[2] The pathogenesis of moyamoya disease is unknown.

Once it begins, the process of blockage (vascular occlusion) tends to continue despite any known medical management. In some people this leads to repeated strokes and severe functional impairment or even death. In others, this blockage may not cause any symptoms.

Moyamoya can be either congenital or acquired. Patients with Down syndrome, neurofibromatosis, or sickle cell disease can develop moyamoya malformations. It is more common in women than in men, although about a third of those affected are male .[3] Brain radiation therapy in children with neurofibromatosis increases the risk of its development.

References

  1. Moyamoya Disease and Moyamoya Syndrome, R. Michael Scott and Edward R. Smith, New England Journal of Medicine, 360:1226-1237, March 19, 2009
  2. Hallemeier C, Rich K, Brubb R, Chicoine M, Moran C, Cross D, Zipfel G, Dacey R, Derdeyn (2006). "Epidemiological features of moyamoya disease in Japan: findings from a nationwide survey". Stroke. 37 (6): 1490–1496. doi:10.1161/01.STR.0000221787.70503.ca. PMID 16645133.
  3. Kuriyama S, Kusaka Y, Fujimura M; et al. (2008). "Prevalence and clinicoepidemiological features of moyamoya disease in Japan: findings from a nationwide epidemiological survey". Stroke. 39 (1): 42–7. doi:10.1161/STROKEAHA.107.490714. PMID 18048855.

Template:WH Template:WS